Tempus, a leader in artificial intelligence and precision medicine, today announced that Ezra Cohen, MD is joining the company as its Chief Medical Officer of Oncology. Dr. Cohen is helping oversee Tempus’ medical operations, with a primary focus on oncology and the company’s patient and provider offerings. In this role, he is applying his deep clinical expertise to the delivery of Tempus’ AI-enabled precision medicine solutions to improve patient care.
Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.
“In the last few years, we have had the opportunity to develop a strong partnership with Dr. Cohen as we worked together to apply Tempus’ precision medicine solutions to his patients’ care,” said Eric Lefkofsky, Founder and CEO of Tempus. “Now as part of our team, we look forward to the insight and expertise he can bring to our efforts to improve patient outcomes and advance research in the field.”
“I have seen first-hand the impact that Tempus’ platform can have in helping physicians like myself deliver personalized patient care,” said Dr. Cohen. “I look forward to joining this talented team to drive its mission forward and revolutionize our approach to research and clinical care.”
Dr. Cohen earned his medical degree at University of Toronto and completed a hematology/oncology fellowship at the University of Chicago, where he was named chief fellow. He is board certified in medical oncology, and a fellow of the Royal College of Physicians and Surgeons of Canada (FRCPSC) and the American Society of Clinical Oncology (FASCO).
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.